Health care pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Grifols has the lowest figure of the 50 health care pharmaceutical companies ranked by P/S ratio, at 0.7, followed by Viatris (1.6) and GSK (2.2). Figures as of 20 Nov 2026, 03:36 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- Lowest
- Grifols0.7
- Median
- 6.7
- Combined market value
- CZK 110.44T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
Health Care▾
Pharmaceuticals▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | GrifolsGRFS · Health Care | 0.7 | CZK 124.2B | CZK 182.50 | 3.19% down | 0% up | ||
| 2 | ViatrisVTRS · Health Care | 1.6 | CZK 507.2B | CZK 442.44 | 1.97% down | 99% up | ||
| 3 | GSKGSK · Health Care | 2.2 | CZK 2.13T | CZK 1,064.27 | 1.56% down | 5% up | ||
| 4 | SanofiSNY · Health Care | 2.3 | CZK 2.46T | CZK 1,025.10 | 2.25% down | 4% down | ||
| 5 | Takeda PharmaceuticalTAK · Health Care | 2.4 | CZK 1.52T | CZK 476.49 | 0.66% up | 51% up | ||
| 6 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | CZK 165.9B | CZK 476.05 | 2.24% down | 90% up | ||
| 7 | Bristol-Myers SquibbBMY · Health Care | 2.5 | CZK 2.65T | CZK 1,298.40 | 2.05% down | 30% up | ||
| 8 | PfizerPFE · Health Care | 2.5 | CZK 3.49T | CZK 612.92 | 1.85% down | 15% up | ||
| 9 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.6 | CZK 1T | CZK 857.73 | 8.74% down | 74% up | ||
| 10 | Elanco Animal HealthELAN · Health Care | 2.8 | CZK 292.5B | CZK 585.10 | 1.54% down | 26% up | ||
| 11 | PTC TherapeuticsPTCT · Health Care | 2.8 | CZK 108.4B | CZK 1,298.06 | 3.16% down | 21% down | ||
| 12 | Legend BiotechLEGN · Health Care | 3.0 | CZK 69.5B | CZK 358.32 | 0.92% down | 41% down | ||
| 13 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | CZK 275.2B | CZK 330.05 | 1.00% down | 8% up | ||
| 14 | ZoetisZTS · Health Care | 3.5 | CZK 730.6B | CZK 1,798.04 | 5.59% down | 26% down | ||
| 15 | Jazz PharmaceuticalsJAZZ · Health Care | 3.6 | CZK 337.8B | CZK 5,262.36 | 4.57% down | 41% up | ||
| 16 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | CZK 264.8B | CZK 1,366.95 | 0.02% down | 17% up | ||
| 17 | Novo NordiskNVO · Health Care | 3.7 | CZK 3.81T | CZK 865.08 | 1.42% down | 17% down | ||
| 18 | Abbott LaboratoriesABT · Health Care | 4.1 | CZK 4T | CZK 2,311.70 | 0.58% down | 16% down | ||
| 19 | AstraZenecaAZN · Health Care | 4.6 | CZK 6.05T | CZK 3,903.87 | 1.87% down | 1% up | ||
| 20 | Ionis PharmaceuticalsIONS · Health Care | 4.8 | CZK 100.9B | CZK 605.80 | 0.62% down | 63% down | ||
| 21 | Merck & CoMRK · Health Care | 5.0 | CZK 7.29T | CZK 2,955.78 | 3.61% down | 45% up | ||
| 22 | NovartisNVS · Health Care | 5.2 | CZK 6.36T | CZK 3,365.51 | 2.57% down | 25% up | ||
| 23 | AlkermesALKS · Health Care | 5.3 | CZK 172.7B | CZK 1,027.77 | 1.43% down | 66% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | 5.3 | CZK 440.6B | CZK 3,289.84 | 1.06% down | 66% down | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 6.7 | CZK 2.13T | CZK 20,549.58 | 2.35% down | 28% up | ||
| 26 | Johnson & JohnsonJNJ · Health Care | 6.8 | CZK 14.31T | CZK 5,945.39 | 2.04% down | 34% up | ||
| 27 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | CZK 137.3B | CZK 971.46 | 1.25% up | 13% up | ||
| 28 | United TherapeuticsUTHR · Health Care | 7.5 | CZK 529.9B | CZK 12,443.16 | 3.16% down | 22% up | ||
| 29 | AbbVieABBV · Health Care | 8.2 | CZK 11.15T | CZK 6,310.38 | 0.86% down | 25% up | ||
| 30 | GenmabGMAB · Health Care | 8.5 | CZK 704.7B | CZK 1,142.83 | 0.75% up | 70% up | ||
| 31 | BeOne MedicinesONC · Health Care | 8.5 | CZK 1.02T | CZK 8,895.60 | 0.97% down | 16% up | ||
| 32 | Corcept TherapeuticsCORT · Health Care | 9.3 | CZK 158.3B | CZK 1,446.18 | 4.15% down | 10% down | ||
| 33 | Travere TherapeuticsTVTX · Health Care | 9.4 | CZK 103.2B | CZK 1,074.95 | 3.86% down | 45% up | ||
| 34 | Madrigal PharmaceuticalsMDGL · Health Care | 9.6 | CZK 205.1B | CZK 8,829.73 | 0.34% down | 27% down | ||
| 35 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 10.8 | CZK 163.6B | CZK 2,081.69 | 1.59% down | 129% up | ||
| 36 | Vertex PharmaceuticalsVRTX · Health Care | 11.0 | CZK 2.94T | CZK 11,587.65 | 2.94% down | 27% up | ||
| 37 | Axsome TherapeuticsAXSM · Health Care | 11.2 | CZK 158.8B | CZK 3,019.65 | 1.25% up | 6% down | ||
| 38 | Mirum PharmaceuticalsMIRM · Health Care | 12.0 | CZK 138.8B | CZK 2,125.64 | 3.27% up | 34% up | ||
| 39 | TG TherapeuticsTGTX · Health Care | 15.9 | CZK 218.2B | CZK 1,443.95 | 1.88% down | 117% up | ||
| 40 | Royalty PharmaRPRX · Health Care | 16.4 | CZK 866.6B | CZK 1,507.16 | 1.38% down | 79% up | ||
| 41 | Eli LillyLLY · Health Care | 18.5 | CZK 26.78T | CZK 30,070.12 | 2.29% down | 33% up | ||
| 42 | Ascendis PharmaASND · Health Care | 21.0 | CZK 373.7B | CZK 5,696.57 | 5.32% down | 29% up | ||
| 43 | Ligand PharmaceuticalsLGND · Health Care | 21.4 | CZK 127.7B | CZK 6,386.05 | 3.94% down | 50% up | ||
| 44 | BridgeBio PharmaBBIO · Health Care | 30.3 | CZK 338.9B | CZK 1,739.95 | 0.22% up | 21% up | ||
| 45 | Rhythm PharmaceuticalsRYTM · Health Care | 42.7 | CZK 180.2B | CZK 2,599.47 | 1.88% down | 18% up | ||
| 46 | InsmedINSM · Health Care | 52.3 | CZK 705.3B | CZK 3,215.06 | 20.58% up | 40% down | ||
| 47 | CytokineticsCYTK · Health Care | 81.4 | CZK 159.5B | CZK 1,145.28 | 0.27% up | 19% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | 176 | CZK 180.2B | CZK 2,760.15 | 2.47% down | 51% up | ||
| 49 | Dianthus TherapeuticsDNTH · Health Care | 2346 | CZK 106.3B | CZK 1,887.95 | 1.01% up | 108% up | ||
| 50 | Roivant SciencesROIV · Health Care | 3418 | CZK 628.3B | CZK 867.08 | 0.59% up | 91% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 22.2557 CZK). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which health care pharmaceutical companies have the lowest P/S ratio?
Grifols (0.7), Viatris (1.6) and GSK (2.2) have the lowest P/S ratio of the 50 health care pharmaceutical companies ranked here as of 20 Nov 2026, 03:36 UTC.
How many health care pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these health care pharmaceutical companies worth together?
The 50 health care pharmaceutical companies ranked by P/S ratio have a combined market value of CZK 110.44T as of 20 Nov 2026, 03:36 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care pharmaceutical companies by P/S ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?sector=health-care&by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.